Cancer Immunotherapy Market 2027 By Therapy, Application, End User and Geography | The Insight Partners

Cancer Immunotherapy Market to 2027 - Global Analysis and Forecasts By Therapy (Monoclonal Antibodies, Immune Checkpoint Inhibitors, Immune System Modulators, Cancer Vaccines); Application (Lung Cancer, Colorectal Cancer, Breast Cancer, Prostate Cancer, Melanoma, Head and neck cancer, Ovarian cancer, Others); End User (Hospitals, Ambulatory Surgery Centers, Cancer Research Centers, Specialty Clinics) and Geography

Report Code: TIPRE00006688 | No. of Pages: 150 | Category: Biotechnology | Status: Upcoming
MARKET INTRODUCTION

Cancer immunotherapy is a therapy that utilizes part of patients' immune system to fight against cancer. The therapy stimulates the person's own immune system to attack the cancer cells. There are different types of immunotherapy that includes monoclonal antibodies, immune checkpoint inhibitors, cancer vaccines and other non-specific immunotherapies. Monoclonal antibodies are man-made antibodies that are used in treating cancer as they recognize specific part of a cancer cell and attacks on it. In recent years, many different types of immunotherapy are being studied for its use against cancer.

MARKET DYNAMICS

The cancer immunotherapy market is expected to grow exponentially in the forecast period owing to the factors such as growing prevalence of cancer, rising adoption of advanced cancer therapies and growing Research and development activities in the cancer immunotherapy field. Furthermore, development of new products coupled with large number of FDA approvals, is anticipated to offer significant growth opportunities in the market during the forecast period.

MARKET SCOPE

The "Global Cancer Immunotherapy Market Analysis to 2027" is a specialized and in-depth study of the biotechnology industry with a particular focus on the global market trend analysis. The report aims to provide an overview of the cancer immunotherapy market with detailed market segmentation by therapy, application, end user, and geography. The global cancer immunotherapy market is expected to witness high growth during the forecast period. The report provides key statistics on the market status of the leading cancer immunotherapy market players and offers key trends and opportunities in the market.

MARKET SEGMENTATION

The global cancer immunotherapy market is segmented on the basis of therapy, application and end user. Based on therapy, the market is classified as monoclonal antibodies, immune checkpoint inhibitors, immune system modulators, and cancer vaccines. Based on application, the market is classified as lung cancer, colorectal cancer, breast cancer, prostate cancer, melanoma, head and neck cancer, ovarian cancer, others. On the basis of end user the cancer immunotherapy market is classified as hospitals, ambulatory surgery centers, cancer research centers, specialty clinics.


REGIONAL FRAMEWORK


The report provides a detailed overview of the industry including both qualitative and quantitative information. It provides overview and forecast of the global cancer immunotherapy market based on various segments. It also provides market size and forecast estimates from year 2017 to 2027 with respect to five major regions, namely; North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA) and South & Central America. The cancer immunotherapy market by each region is later sub-segmented by respective countries and segments. The report covers analysis and forecast of 18 countries globally along with current trend and opportunities prevailing in the region.

The report analyzes factors affecting cancer immunotherapy market from both demand and supply side and further evaluates market dynamics effecting the market during the forecast period i.e., drivers, restraints, opportunities, and future trend. The report also provides exhaustive PEST analysis for all five regions namely; North America, Europe, APAC, MEA and South & Central America after evaluating political, economic, social and technological factors affecting the cancer immunotherapy market in these regions.

MARKET PLAYERS


The reports cover key developments in the cancer immunotherapy market as organic and inorganic growth strategies. Various companies are focusing on organic growth strategies such as product launches, product approvals and others such as patents and events. Inorganic growth strategies activities witnessed in the market were acquisitions, and partnership & collaborations. These activities have paved way for expansion of business and customer base of market players. The market payers from cancer immunotherapy market are anticipated to lucrative growth opportunities in the future with the rising demand for cancer immunotherapy market in the global market. Below mentioned is the list of few companies engaged in the cancer immunotherapy market.

The report also includes the profiles of key cancer immunotherapy market companies along with their SWOT analysis and market strategies. In addition, the report focuses on leading industry players with information such as company profiles, components and services offered, financial information of last 3 years, key development in past five years.

  •  F. Hoffmann-La Roche AG
  •  Advaxis Inc.
  •  Merck & Co., Inc.
  •  Eli Lilly and Company
  •  Bristol-Myers Squibb Company
  •  Pfizer Inc.
  •  Novartis AG
  •  Bayer AG
  •  Immunomedics Inc.
  •  Astrazeneca plc.

The Insight Partner's dedicated research and analysis team consist of experienced professionals with advanced statistical expertise and offer various customization options in the existing study.
TABLE OF CONTENTS

1. INTRODUCTION
1.1. SCOPE OF THE STUDY
1.2. THE INSIGHT PARTNERS RESEARCH REPORT GUIDANCE
1.3. MARKET SEGMENTATION
1.3.1 Cancer Immunotherapy Market - By Therapy
1.3.2 Cancer Immunotherapy Market - By Application
1.3.3 Cancer Immunotherapy Market - By End User
1.3.4 Cancer Immunotherapy Market - By Region
1.3.4.1 By Country

2. KEY TAKEAWAYS

3. RESEARCH METHODOLOGY

4. CANCER IMMUNOTHERAPY MARKET LANDSCAPE
4.1. OVERVIEW
4.2. PEST ANALYSIS
4.2.1 North America - Pest Analysis
4.2.2 Europe - Pest Analysis
4.2.3 Asia-Pacific - Pest Analysis
4.2.4 Middle East and Africa - Pest Analysis
4.2.5 South and Central America - Pest Analysis
4.3. EXPERT OPINIONS

5. CANCER IMMUNOTHERAPY MARKET - KEY MARKET DYNAMICS

5.1. KEY MARKET DRIVERS
5.2. KEY MARKET RESTRAINTS
5.3. KEY MARKET OPPORTUNITIES
5.4. FUTURE TRENDS
5.5. IMPACT ANALYSIS OF DRIVERS AND RESTRAINTS

6. CANCER IMMUNOTHERAPY MARKET - GLOBAL MARKET ANALYSIS

6.1. CANCER IMMUNOTHERAPY - GLOBAL MARKET OVERVIEW
6.2. CANCER IMMUNOTHERAPY - GLOBAL MARKET AND FORECAST TO 2027
6.3. MARKET POSITIONING/MARKET SHARE

7. CANCER IMMUNOTHERAPY MARKET - REVENUE AND FORECASTS TO 2027 - THERAPY

7.1. OVERVIEW
7.2. THERAPY MARKET FORECASTS AND ANALYSIS
7.3. MONOCLONAL ANTIBODIES
7.3.1. Overview
7.3.2. Monoclonal Antibodies Market Forecast and Analysis
7.4. IMMUNE CHECKPOINT INHIBITORS
7.4.1. Overview
7.4.2. Immune Checkpoint Inhibitors Market Forecast and Analysis
7.4.3. PD-1/PD-L1 Market
7.4.3.1. Overview
7.4.3.2. PD-1/PD-L1 Market Forecast and Analysis
7.4.4. CTLA-4 Market
7.4.4.1. Overview
7.4.4.2. CTLA-4 Market Forecast and Analysis
7.5. IMMUNE SYSTEM MODULATORS
7.5.1. Overview
7.5.2. Immune System Modulators Market Forecast and Analysis
7.6. CANCER VACCINES
7.6.1. Overview
7.6.2. Cancer Vaccines Market Forecast and Analysis

8. CANCER IMMUNOTHERAPY MARKET - REVENUE AND FORECASTS TO 2027 - APPLICATION

8.1. OVERVIEW
8.2. APPLICATION MARKET FORECASTS AND ANALYSIS
8.3. LUNG CANCER
8.3.1. Overview
8.3.2. Lung Cancer Market Forecast and Analysis
8.4. COLORECTAL CANCER
8.4.1. Overview
8.4.2. Colorectal Cancer Market Forecast and Analysis
8.5. BREAST CANCER
8.5.1. Overview
8.5.2. Breast Cancer Market Forecast and Analysis
8.6. PROSTATE CANCER
8.6.1. Overview
8.6.2. Prostate Cancer Market Forecast and Analysis
8.7. MELANOMA
8.7.1. Overview
8.7.2. Melanoma Market Forecast and Analysis
8.8. HEAD AND NECK CANCER
8.8.1. Overview
8.8.2. Head and neck cancer Market Forecast and Analysis
8.9. OVARIAN CANCER
8.9.1. Overview
8.9.2. Ovarian cancer Market Forecast and Analysis
8.10. OTHERS
8.10.1. Overview
8.10.2. Others Market Forecast and Analysis

9. CANCER IMMUNOTHERAPY MARKET - REVENUE AND FORECASTS TO 2027 - END USER

9.1. OVERVIEW
9.2. END USER MARKET FORECASTS AND ANALYSIS
9.3. HOSPITALS
9.3.1. Overview
9.3.2. Hospitals Market Forecast and Analysis
9.4. AMBULATORY SURGERY CENTERS
9.4.1. Overview
9.4.2. Ambulatory Surgery Centers Market Forecast and Analysis
9.5. CANCER RESEARCH CENTERS
9.5.1. Overview
9.5.2. Cancer Research Centers Market Forecast and Analysis
9.6. SPECIALTY CLINICS
9.6.1. Overview
9.6.2. Specialty Clinics Market Forecast and Analysis

10. CANCER IMMUNOTHERAPY MARKET REVENUE AND FORECASTS TO 2027 - GEOGRAPHICAL ANALYSIS

10.1. NORTH AMERICA
10.1.1 North America Cancer Immunotherapy Market Overview
10.1.2 North America Cancer Immunotherapy Market Forecasts and Analysis
10.1.3 North America Cancer Immunotherapy Market Forecasts and Analysis - By Therapy
10.1.4 North America Cancer Immunotherapy Market Forecasts and Analysis - By Application
10.1.5 North America Cancer Immunotherapy Market Forecasts and Analysis - By End User
10.1.6 North America Cancer Immunotherapy Market Forecasts and Analysis - By Countries
10.1.6.1 United States Cancer Immunotherapy Market
10.1.6.1.1 United States Cancer Immunotherapy Market by Therapy
10.1.6.1.2 United States Cancer Immunotherapy Market by Application
10.1.6.1.3 United States Cancer Immunotherapy Market by End User
10.1.6.2 Canada Cancer Immunotherapy Market
10.1.6.2.1 Canada Cancer Immunotherapy Market by Therapy
10.1.6.2.2 Canada Cancer Immunotherapy Market by Application
10.1.6.2.3 Canada Cancer Immunotherapy Market by End User
10.1.6.3 Mexico Cancer Immunotherapy Market
10.1.6.3.1 Mexico Cancer Immunotherapy Market by Therapy
10.1.6.3.2 Mexico Cancer Immunotherapy Market by Application
10.1.6.3.3 Mexico Cancer Immunotherapy Market by End User
10.2. EUROPE
10.2.1 Europe Cancer Immunotherapy Market Overview
10.2.2 Europe Cancer Immunotherapy Market Forecasts and Analysis
10.2.3 Europe Cancer Immunotherapy Market Forecasts and Analysis - By Therapy
10.2.4 Europe Cancer Immunotherapy Market Forecasts and Analysis - By Application
10.2.5 Europe Cancer Immunotherapy Market Forecasts and Analysis - By End User
10.2.6 Europe Cancer Immunotherapy Market Forecasts and Analysis - By Countries
10.2.6.1 Germany Cancer Immunotherapy Market
10.2.6.1.1 Germany Cancer Immunotherapy Market by Therapy
10.2.6.1.2 Germany Cancer Immunotherapy Market by Application
10.2.6.1.3 Germany Cancer Immunotherapy Market by End User
10.2.6.2 France Cancer Immunotherapy Market
10.2.6.2.1 France Cancer Immunotherapy Market by Therapy
10.2.6.2.2 France Cancer Immunotherapy Market by Application
10.2.6.2.3 France Cancer Immunotherapy Market by End User
10.2.6.3 Italy Cancer Immunotherapy Market
10.2.6.3.1 Italy Cancer Immunotherapy Market by Therapy
10.2.6.3.2 Italy Cancer Immunotherapy Market by Application
10.2.6.3.3 Italy Cancer Immunotherapy Market by End User
10.2.6.4 Spain Cancer Immunotherapy Market
10.2.6.4.1 Spain Cancer Immunotherapy Market by Therapy
10.2.6.4.2 Spain Cancer Immunotherapy Market by Application
10.2.6.4.3 Spain Cancer Immunotherapy Market by End User
10.2.6.5 United Kingdom Cancer Immunotherapy Market
10.2.6.5.1 United Kingdom Cancer Immunotherapy Market by Therapy
10.2.6.5.2 United Kingdom Cancer Immunotherapy Market by Application
10.2.6.5.3 United Kingdom Cancer Immunotherapy Market by End User
10.3. ASIA-PACIFIC
10.3.1 Asia-Pacific Cancer Immunotherapy Market Overview
10.3.2 Asia-Pacific Cancer Immunotherapy Market Forecasts and Analysis
10.3.3 Asia-Pacific Cancer Immunotherapy Market Forecasts and Analysis - By Therapy
10.3.4 Asia-Pacific Cancer Immunotherapy Market Forecasts and Analysis - By Application
10.3.5 Asia-Pacific Cancer Immunotherapy Market Forecasts and Analysis - By End User
10.3.6 Asia-Pacific Cancer Immunotherapy Market Forecasts and Analysis - By Countries
10.3.6.1 Australia Cancer Immunotherapy Market
10.3.6.1.1 Australia Cancer Immunotherapy Market by Therapy
10.3.6.1.2 Australia Cancer Immunotherapy Market by Application
10.3.6.1.3 Australia Cancer Immunotherapy Market by End User
10.3.6.2 China Cancer Immunotherapy Market
10.3.6.2.1 China Cancer Immunotherapy Market by Therapy
10.3.6.2.2 China Cancer Immunotherapy Market by Application
10.3.6.2.3 China Cancer Immunotherapy Market by End User
10.3.6.3 India Cancer Immunotherapy Market
10.3.6.3.1 India Cancer Immunotherapy Market by Therapy
10.3.6.3.2 India Cancer Immunotherapy Market by Application
10.3.6.3.3 India Cancer Immunotherapy Market by End User
10.3.6.4 Japan Cancer Immunotherapy Market
10.3.6.4.1 Japan Cancer Immunotherapy Market by Therapy
10.3.6.4.2 Japan Cancer Immunotherapy Market by Application
10.3.6.4.3 Japan Cancer Immunotherapy Market by End User
10.3.6.5 South Korea Cancer Immunotherapy Market
10.3.6.5.1 South Korea Cancer Immunotherapy Market by Therapy
10.3.6.5.2 South Korea Cancer Immunotherapy Market by Application
10.3.6.5.3 South Korea Cancer Immunotherapy Market by End User
10.4. MIDDLE EAST AND AFRICA
10.4.1 Middle East and Africa Cancer Immunotherapy Market Overview
10.4.2 Middle East and Africa Cancer Immunotherapy Market Forecasts and Analysis
10.4.3 Middle East and Africa Cancer Immunotherapy Market Forecasts and Analysis - By Therapy
10.4.4 Middle East and Africa Cancer Immunotherapy Market Forecasts and Analysis - By Application
10.4.5 Middle East and Africa Cancer Immunotherapy Market Forecasts and Analysis - By End User
10.4.6 Middle East and Africa Cancer Immunotherapy Market Forecasts and Analysis - By Countries
10.4.6.1 South Africa Cancer Immunotherapy Market
10.4.6.1.1 South Africa Cancer Immunotherapy Market by Therapy
10.4.6.1.2 South Africa Cancer Immunotherapy Market by Application
10.4.6.1.3 South Africa Cancer Immunotherapy Market by End User
10.4.6.2 Saudi Arabia Cancer Immunotherapy Market
10.4.6.2.1 Saudi Arabia Cancer Immunotherapy Market by Therapy
10.4.6.2.2 Saudi Arabia Cancer Immunotherapy Market by Application
10.4.6.2.3 Saudi Arabia Cancer Immunotherapy Market by End User
10.4.6.3 U.A.E Cancer Immunotherapy Market
10.4.6.3.1 U.A.E Cancer Immunotherapy Market by Therapy
10.4.6.3.2 U.A.E Cancer Immunotherapy Market by Application
10.4.6.3.3 U.A.E Cancer Immunotherapy Market by End User
10.5. SOUTH AND CENTRAL AMERICA
10.5.1 South and Central America Cancer Immunotherapy Market Overview
10.5.2 South and Central America Cancer Immunotherapy Market Forecasts and Analysis
10.5.3 South and Central America Cancer Immunotherapy Market Forecasts and Analysis - By Therapy
10.5.4 South and Central America Cancer Immunotherapy Market Forecasts and Analysis - By Application
10.5.5 South and Central America Cancer Immunotherapy Market Forecasts and Analysis - By End User
10.5.6 South and Central America Cancer Immunotherapy Market Forecasts and Analysis - By Countries
10.5.6.1 Brazil Cancer Immunotherapy Market
10.5.6.1.1 Brazil Cancer Immunotherapy Market by Therapy
10.5.6.1.2 Brazil Cancer Immunotherapy Market by Application
10.5.6.1.3 Brazil Cancer Immunotherapy Market by End User
10.5.6.2 Argentina Cancer Immunotherapy Market
10.5.6.2.1 Argentina Cancer Immunotherapy Market by Therapy
10.5.6.2.2 Argentina Cancer Immunotherapy Market by Application
10.5.6.2.3 Argentina Cancer Immunotherapy Market by End User

11. INDUSTRY LANDSCAPE

11.1. MERGERS AND ACQUISITIONS
11.2. AGREEMENTS, COLLABORATIONS AND JOIN VENTURES
11.3. NEW PRODUCT LAUNCHES
11.4. EXPANSIONS AND OTHER STRATEGIC DEVELOPMENTS

12. CANCER IMMUNOTHERAPY MARKET, KEY COMPANY PROFILES

12.1. F. HOFFMANN-LA ROCHE AG
12.1.1. Key Facts
12.1.2. Business Description
12.1.3. Products and Services
12.1.4. Financial Overview
12.1.5. SWOT Analysis
12.1.6. Key Developments
12.2. ADVAXIS INC.
12.2.1. Key Facts
12.2.2. Business Description
12.2.3. Products and Services
12.2.4. Financial Overview
12.2.5. SWOT Analysis
12.2.6. Key Developments
12.3. MERCK AND CO., INC.
12.3.1. Key Facts
12.3.2. Business Description
12.3.3. Products and Services
12.3.4. Financial Overview
12.3.5. SWOT Analysis
12.3.6. Key Developments
12.4. ELI LILLY AND COMPANY
12.4.1. Key Facts
12.4.2. Business Description
12.4.3. Products and Services
12.4.4. Financial Overview
12.4.5. SWOT Analysis
12.4.6. Key Developments
12.5. BRISTOL-MYERS SQUIBB COMPANY
12.5.1. Key Facts
12.5.2. Business Description
12.5.3. Products and Services
12.5.4. Financial Overview
12.5.5. SWOT Analysis
12.5.6. Key Developments
12.6. PFIZER INC.
12.6.1. Key Facts
12.6.2. Business Description
12.6.3. Products and Services
12.6.4. Financial Overview
12.6.5. SWOT Analysis
12.6.6. Key Developments
12.7. NOVARTIS AG
12.7.1. Key Facts
12.7.2. Business Description
12.7.3. Products and Services
12.7.4. Financial Overview
12.7.5. SWOT Analysis
12.7.6. Key Developments
12.8. BAYER AG
12.8.1. Key Facts
12.8.2. Business Description
12.8.3. Products and Services
12.8.4. Financial Overview
12.8.5. SWOT Analysis
12.8.6. Key Developments
12.9. IMMUNOMEDICS INC.
12.9.1. Key Facts
12.9.2. Business Description
12.9.3. Products and Services
12.9.4. Financial Overview
12.9.5. SWOT Analysis
12.9.6. Key Developments
12.10. ASTRAZENECA PLC.
12.10.1. Key Facts
12.10.2. Business Description
12.10.3. Products and Services
12.10.4. Financial Overview
12.10.5. SWOT Analysis
12.10.6. Key Developments

13. APPENDIX

13.1. ABOUT THE INSIGHT PARTNERS
13.2. GLOSSARY OF TERMS
The List of Companies

1. F. Hoffmann-La Roche AG
2. Advaxis Inc.
3. Merck & Co., Inc.
4. Eli Lilly and Company
5. Bristol-Myers Squibb Company
6. Pfizer Inc.
7. Novartis AG
8. Bayer AG
9. Immunomedics Inc.
10. Astrazeneca plc.